Patents Examined by Dameron Jones
-
Patent number: 6238644Abstract: The instant invention utilizes the preferential uptake of iodine by mammary cells in general, and neoplastic mammary cells in particular to promote the concentration of radioactive iodine in malignant mammary cells. Radioactive iodine has utility in the instant invention as both a cancer therapeutic and a radioimaging dye. Iodine 125 and/or iodine 131 are administered in doses from 1 to 50 milliCurie per day. Subsequent doses may also be administered as clinically warranted. Administration of hormones prior to, or simultaneous with, the administration of the radio iodine is optionally utilized to stimulate iodine uptake in neoplastic mammary cells or to inhibit iodine uptake by the thyroid gland.Type: GrantFiled: September 2, 1998Date of Patent: May 29, 2001Assignee: Wayne State UniversityInventor: James A. Rillema
-
Patent number: 6231833Abstract: Substituted pyrido[1,2-a]pyrazines of general formula I; wherein Ar and Ar1 represent various carbocyclic and heterocyclic aromatic rings; A represents O, S, SO, SO2, CHOH, C═O, or —(CR3R4); and n is 0-2, as well as precursors thereto, are ligands for dopamine receptor subtypes and serotonin (5HT) within the body and are therefore useful in the treatment of disorders of the dopamine and serotonin systems:Type: GrantFiled: August 5, 1999Date of Patent: May 15, 2001Assignee: Pfizer IncInventors: Kishor A. Desai, Anton F. J. Fliri, Mark A. Sanner
-
Patent number: 6217844Abstract: Improved methods for detecting lesions in dense breast tissue are disclosed. The methods of the invention generally feature administration to a subject of an LHRH antagonist in an amount and for a period of time sufficient to reduce the density of breast tissue prior to generating an image of the breast tissue, for example by mammography, to detect a lesion in the breast tissue. Packaged formulations for reducing breast density in a subject prior to generating an image of the subject's breast tissue, comprising an LHRH antagonist packaged with instructions for using the LHRH antagonist to reduce breast density in a subject prior to imaging the breast tissue, are also disclosed.Type: GrantFiled: April 27, 1998Date of Patent: April 17, 2001Assignee: Praecis Pharmaceuticals, Inc.Inventor: Marc B. Garnick
-
Patent number: 6214316Abstract: This invention relates to therapeutic reagents and peptides, including radiotherapeutic reagents and peptides, radiodiagnostic reagents and peptides, and methods for producing labeled radiodiagnostic agents. Specifically, the invention relates to cyclic peptide derivatives and analogs of somatostatin, and embodiments of such peptides radiolabeled with a radioisotope, as well as methods and kits for making, radiolabeling and using such peptides for radiodiagnostic and radiotherapeutic purposes. The invention specifically relates to cyclic peptide derivatives and analogues of somatostatin radiolabeled with technetium-99m and uses thereof as scintigraphic imaging agents. The invention also specifically relates to cyclic peptide derivatives and analogues of somatostatin radiolabeled with cytotoxic radioisotopes such as rhenium-186 (186Re) and rhenium-188 (188Re) for use as radiotherapeutic agents.Type: GrantFiled: October 19, 1999Date of Patent: April 10, 2001Assignee: Diatide, Inc.Inventor: Richard T. Dean
-
Patent number: 6210653Abstract: Low molecular weight polystyrenes containing sulfonic acids and their salts or low molecular weight sulfonated polystyrene copolymers used as anti-viral agents against enveloped viruses such as HIV. These compounds have been shown to be effective in in vitro testing against HIV at subtoxic concentrations.Type: GrantFiled: November 9, 1999Date of Patent: April 3, 2001Inventors: Arturo G. Bellettini, Richard J. Bellettini
-
Patent number: 6207136Abstract: A fluorescent imaging method of the changes in viability of living bodies wherein the living bodies are provided with a chemical or physical exterior stimulation and information on the changes in viability of cells caused by the stimulation is obtained by means of a fluorescent imaging method of the saccharide uptake activity by contacting or administering to the living bodies an aqueous solution of a fluorescent saccharide compound which includes at its specific position a saccharide molecule chemically combined with a fluorescent pigment molecule.Type: GrantFiled: January 15, 1998Date of Patent: March 27, 2001Assignee: Tokyo University of Agriculture and TechnologyInventor: Hideaki Matsuoka
-
Patent number: 6203775Abstract: A method of labelling a protein with a metal involving chelating a metal to a compound, with a molecular weight of at least 1,000, and a reactive group capable of forming a covalent bond with a target protein, and conjugating the metallically-labelled compound to a protein.Type: GrantFiled: March 19, 1993Date of Patent: March 20, 2001Assignee: The General Hospital CorporationInventors: Vladimir P. Torchilin, Vladimir S. Trubetskoy
-
Patent number: 6203776Abstract: Disclosed are methods to identify adrenergic receptor antagonists having good tolerability. These methods include measuring the inverse agonist activity and/or the intrinsic sympathomimetic activity of an adrenergic receptor antagonist. Also disclosed are a method to treat heart failure and compounds useful therefor.Type: GrantFiled: March 25, 1998Date of Patent: March 20, 2001Assignee: University Technology CorporationInventors: Michael R. Bristow, J. David Port
-
Patent number: 6200546Abstract: A compound for use as a therapeutic or diagnostic radiopharmaceutical includes a group capable of complexing a medically useful metal attached to a moiety which is capable of binding to a gastrin releasing peptide receptor. A method for treating a subject having a neoplastic disease includes administering to the subject an effective amount of a radiopharmaceutical having a metal chelated with a chelating group attached to a moiety capable of binding to a gastrin releasing peptide receptor expressed on tumor cells with subsequent internalization inside of the cell. A method of forming a therapeutic or diagnostic compound includes reacting a metal synthon with a chelating group covalently linked with a moiety capable of binding a gastrin releasing peptide receptor.Type: GrantFiled: April 22, 1998Date of Patent: March 13, 2001Assignee: The Curators of the University of MissouriInventors: Timothy J. Hoffman, Wynn A. Volkert, Ning Li, Gary Sieckman, C. A. Higginbotham
-
Patent number: 6200594Abstract: Topical and oral compositions containing unique blends of certain herbs effectively enhance breasts in human females by strengthening connective tissues and encouraging the growth of new cells. The topical composition contains Saw Palmetto berry extract, Chaste Tree berry extract, Fenugreek seed extract, Fennel seed extract, Comfrey extract, White Willow Bark extract, Ma Huang extract, Black Cohosh extract, Guarana extract, Passion Flower extract, Bilberry extract, Horsetail extract and Cayenne extract. The oral composition is a dietary supplement system containing two diet supplement compositions. The first composition contains extracts of Blessed Thistle, Hops, Wild Yam, Fenugreek seed, Saw Palmetto berry, Chaste Tree berry, Fennel seed, Black Cohosh, Damiana, Dong Quai, Lycium Chinese Herb, Scullcap Concentrate, and Curcubita Pepo Pumpkin seed, as well as Methyl Sulfonyl Methane and Royal Jelly.Type: GrantFiled: December 29, 1999Date of Patent: March 13, 2001Assignee: Vital Dynamics, Inc.Inventors: Joseph Michael Ernest, Allen Smith
-
Patent number: 6197986Abstract: Organo silicon compound having the following general formula (I): R4—Si (OR1) (OR2) (R3) (I) where R1 and R2 each one independently represent an atom of hydrogen or an alkyl group, R3 represents an hydrogen atom, an hydroxyl group, an amine group, an alkyl group, an alkoxy or a carboxylate group, and at least one of the OR1, OR2 or R3 groups represents an hydroxyl group, R4 represents an alkyl group substituted or not by a functional group such as, notably, an alkyl phosphate group or an alkyl phosphonate group, or any other group for which the R4—Si bond is not hydrolyzable, and the compound: is in solid form, and/or is possibly associated with at least one stabilizer, and/or is possibly associated with at least one dispersant.Type: GrantFiled: March 24, 1998Date of Patent: March 6, 2001Assignee: Exsymol S.A.M.Inventors: Marie-Christine Seguin, Jean Gueyne
-
Patent number: 6193948Abstract: An isolated nucleic acid sequence encoding Hu paraneoplastic antigenic polypeptide is provided by this invention. This invention also provides a purified Hu antigenic polypeptide and compositions containing the purified Hu antigenic polypeptide. Further provided by this invention is a monoclonal antibody directed to an epitope on the Hu paraneoplastic antigenic polypeptide. Compositions containing this monoclonal antibody also are provided by this invention. This invention also provides methods of diagnosis and treatment using the compositions described hereinabove.Type: GrantFiled: May 21, 1998Date of Patent: February 27, 2001Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Jerome B. Posner, Henry M. Furneaux
-
Patent number: 6190641Abstract: The sensitivity and specificity of the optical modality can be enhanced by the use of highly absorbing dyes as contrast agents. Novel indocyanine dyes that absorb and emit light in the near infrared region of electromagnetic spectrum are disclosed. These dyes are useful for imaging, diagnosis and therapy of various diseased states. Particularly, the molecules of the invention are useful for optical diagnostic imaging and therapy, in endoscopic applications for the detection of tumors and other abnormalities, for localized therapy, for photoacoustic tumor imaging, detection and therapy, and for sonofluorescence tumor imaging, detection and therapy.Type: GrantFiled: January 18, 2000Date of Patent: February 20, 2001Assignee: Mallinckrodt Inc.Inventors: Samuel Achilefu, Raghavan Rajagopalan, Richard B. Dorshow, Joseph E. Bugaj
-
Patent number: 6191262Abstract: In the metallation of complexing agents such as DTPA-BMA with a lanthanide using a lanthanide oxide such as the lanthanide source, oxalic acid is used as a reaction accelerator.Type: GrantFiled: October 15, 1999Date of Patent: February 20, 2001Assignee: Nycomed Imaging AsInventors: Ole Homestad, Espen Myrbraten
-
Patent number: 6187286Abstract: The invention provides tumor imaging agents comprising a radionuclide in association with a nucleotide polyphosphate targeting molecule. Methods for using the tumor imaging agents and kits containing the tumor imaging agents or components suitable for production of the tumor imaging agents are also provided.Type: GrantFiled: May 1, 1997Date of Patent: February 13, 2001Assignee: The General Hospital CorporationInventors: David R. Elmaleh, John W. Babich
-
Patent number: 6187911Abstract: A method for separating a desired metal or metalloi from impurities using a supercritical extraction process based on solubility differences between the components, as well as the ability to vary the solvent power of the supercritical fluid, is described. The use of adduct-forming agents, such as phosphorous-containing ligands, to separate metal or metalloid chelates in such processes is further disclosed. In preferred embodiments, the extraction solvent is supercritical carbon dioxide and the chelating agent is selected from the group consisting of &bgr;-diketones; phosphine oxides, such as trialkylphosphine oxides, triarylphosphine oxides and alkylarylphosphine oxides; phosphinic acids; carboxylic acids; phosphates, such as trialkylphosphates, triarylphosphates and alkylarylphosphates; crown ethers; dithiocarbamates; phosphine sulfides; phosphorothioic acids; thiophosphinic acids; halogenated analogs of these chelating agents; and mixtures of these chelating agents.Type: GrantFiled: May 7, 1999Date of Patent: February 13, 2001Assignee: Idaho Research Foundation, Inc.Inventors: Chien M. Wai, Neil G. Smart, Cindy Phelps
-
Patent number: 6183721Abstract: Compounds of formula I wherein M is a cation equivalent and A is Phe or Tyr, in free form or in salt form are useful as radiopharmaceuticals when complexed with a radionuclide.Type: GrantFiled: April 23, 1997Date of Patent: February 6, 2001Assignee: Novartis AGInventors: Rainer Albert, Christian Bruns, Peter Smith-Jones, Barbara Stolz, Gisbert Weckbecker
-
Patent number: 6183726Abstract: The sensitivity and specificity of the optical modality can be enhanced by the use of highly absorbing dyes as contrast agents. Novel cyanine dyes that absorb and emit light in the near infrared region of electromagnetic spectrum are disclosed. These dyes are useful for imaging, diagnosis and therapy of various diseased states. Particularly, the molecules of the invention are useful for optical diagnostic imaging and therapy, in endoscopic applications for the detection of tumors and other abnormalities, for localized therapy, for photoacoustic tumor imaging, detection and therapy, and for sonofluorescence tumor imaging, detection and therapy.Type: GrantFiled: January 18, 2000Date of Patent: February 6, 2001Assignee: Mallinckrodt Inc.Inventors: Samuel Achilefu, Raghavan Rajagopalan, Richard B. Dorshow, Joseph E. Bugaj
-
Patent number: 6184361Abstract: Novel methods, processes and metal complexes attached to a hypoxia-localizing moiety comprising a metal, preferably radionuclide of rhenium or technetium; a hypoxia-localizing moiety; and, a complexing ligand, wherein said ligand and said radionuclide combined have cell membrane permeabilities greater than that of sucrose, are disclosed.Type: GrantFiled: June 6, 1995Date of Patent: February 6, 2001Assignee: Bracco International B.V.Inventors: Karen Linder, Adrian D. Nunn, David P. Nowotnik, Kondareddiar Ramalingam, Richard J. DiRocco, William L. Rumsey, John P. Pirro
-
Patent number: 6183722Abstract: This invention relates to therapeutic reagents and peptides, including radiotherapeutic reagents and peptides, radiodiagnostic reagents and peptides, and methods for producing labeled radiodiagnostic agents. Specifically, the invention relates to cyclic peptide derivatives and analogs of somatostatin, and embodiments of such peptides radiolabeled with a radioisotope, as well as methods and kits for making, radiolabeling and using such peptides for radiodiagnostic and radiotherapeutic purposes. The invention specifically relates to cyclic peptide derivatives and analogues of somatostatin radiolabeled with technetium-99m and uses thereof as scintigraphic imaging agents. The invention also specifically relates to cyclic peptide derivatives and analogues of somatostatin radiolabeled with cytotoxic radioisotopes such as rhenium-186 (186Re) and rhenium-188 (188Re) for use as radiotherapeutic agents.Type: GrantFiled: October 19, 1999Date of Patent: February 6, 2001Assignee: Diatide, Inc.Inventors: Richard T. Dean, John Lister-James